LLY

Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.

Walmart (NasdaqGS:WMT) is set to enter the top 10 of the Russell 3000 Index during the June 2026 reconstitution, replacing Eli Lilly. The index change follows Q1 results where Walmart reported record sales alongside a cautious earnings outlook that triggered a sharp stock pullback. Two senior executives are leaving the company as Walmart reshapes its leadership team and refines its long term priorities. For you as an investor, Walmart sits at the crossroads of big box retail, grocery, and e...

Eli Lilly (NYSE:LLY) announced a US$3.8b series of acquisitions in vaccines, including Curevo, LimmaTech Biologics, and Vaccine Company. The company is expanding its presence in infectious disease prevention alongside its established obesity and diabetes drug portfolio. Phase 3 trial results for Eli Lilly’s obesity drug candidate retatrutide showed record weight loss outcomes and strong efficacy signals. These developments introduce fresh data points for investors tracking Eli Lilly’s R&D...

(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivPutin Signs Law on Use of Army to Aid Russians Detained AbroadThese AI Gurus Are Charging

Positive Phase 1b results support plans for a Phase 2 trial later this year.

The drugmaker is buying three vaccine developers to strengthen its infectious disease pipeline.

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...

"Micron's great," Trump said as the chipmaker topped $1 trillion. Prediction markets are now betting on whether Washington takes a stake next.(